拜玛林制药 BMRN 深 沪
等待开盘 12-19 09:30:00 美东时间
51.95
+0.150
+0.29%
华盛通- 最 高52.29
- 今 开51.57
- 成交量 213.71万股
- 最 低 51.50
- 昨 收 51.80
- 总市值 99.74亿
- 52周最高 73.51
- 市盈率 静 23.54
- 换手率 1.11%
- 52周最低 50.76
- 委 比 -25.41%
- 总股本 1.92亿
- 历史最高 151.75
- 量 比 1.09
- 振 幅 1.53%
- 历史最低 23.735
- 每 手 1
- 风险率 5.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screenings' - HHS
https://www.hhs.gov/press-room/secretary-kennedy-adds-duchenne-muscular-dystrophy-metachromatic-leukodystrophy-to-newborn-screenings.html#:~:text=WASHINGTON%E2%80%94DECEMBER%2016%2C%202025%20%E2%80%94,scientific%20review
12-17 00:34
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
12-04 09:38
Leerink Partners Downgrades BioMarin Pharmaceutical to Market Perform, Lowers Price Target to $60
Leerink Partners analyst Joseph Schwartz downgrades BioMarin Pharmaceutical (NASDAQ:BMRN) from Outperform to Market Perform and lowers the price target from $82 to $60.
12-03 21:35
Goldman says healthcare is ripe for stock picking; here's some they like
The healthcare sector’s slump had created opportunities for stock-pickers rather than broad sector gains, Goldman Sachs strategist David Kostin said. Healthcare (XLV) has lagged the S&P 500 (SPY) (IVV...
11-11 00:19
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Stifel Downgrades BioMarin Pharmaceutical to Hold, Lowers Price Target to $61
Stifel analyst Paul Matteis downgrades BioMarin Pharmaceutical (NASDAQ:BMRN) from Buy to Hold and lowers the price target from $73 to $61.
11-06 20:48
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
10-29 09:25
BioMarin为其药物VOXZOGO设定2025年9-9.35亿美元营收目标
美股周二早盘，生物技术企业BioMarin Pharmaceutical （BMRN）股价上涨4.4%，此前该公司为其药物VOXZOGO设定2025年9-...
10-28 23:00
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $98
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $104 to $98.
10-28 19:15
